T3D Therapeutics Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $5M
Latest Deal Amount
  • Investors
  • 1

T3D Therapeutics General Information

Description

Developer of a novel drug therapy designed to stop or reverse the course of Alzheimer's disease. The company's drug is an orally-delivered once-a-day medicine that targets both the brain 'starvation' and neurodegeneration of Alzheimer's disease and helps in treating multiple manifestations of the disease, enabling Alzheimer patients to have a drug that can potentially improve multiple defects and improve memory, motor function and cognition.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare
Primary Office
  • 68 T.W. Alexander Drive
  • Post Office Box 13628
  • Research Triangle Park, NC 27709
  • United States
+1 (919) 000-0000

T3D Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

T3D Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Grant 01-Aug-2020 $5M 000.00 0000 Completed Clinical Trials - Phase 2
9. Later Stage VC (Series B) 04-Nov-2019 0000 000.00 Completed Generating Revenue
8. Grant 20-May-2019 000 000.00 Completed Clinical Trials - Phase 2
7. Early Stage VC (Series B) 10-Mar-2018 000 000.00 0000 Completed Clinical Trials - Phase 2
6. Early Stage VC (Series A3) 11-Mar-2016 00.000 00.000 0000 Completed Clinical Trials - Phase 2
5. Grant 24-Mar-2015 00.000 00.00 Completed Clinical Trials - Phase 2
4. Debt - General 31-Jul-2014 00000 00.00 Completed Startup
3. Early Stage VC (Series A2) 14-Mar-2014 00000 00.000 00.000 Completed Startup
2. Debt - General 24-Jun-2013 $50K $487K Completed Startup
1. Angel (individual) 20-Jun-2013 $437K $437K 00.000 Completed Startup
To view T3D Therapeutics’s complete valuation and funding history, request access »

T3D Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3 0,000,000 00.000000 00 00 00 00 00 0.000
Series A2 000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A1 404,628 $0.001000 6% $1.08 $1.08 1x $1.08 7.26%
To view T3D Therapeutics’s complete cap table history, request access »

T3D Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a novel drug therapy designed to stop or reverse the course of Alzheimer's disease. The company's drug is a
Drug Discovery
Research Triangle Park, NC
6 As of 2020
000.00
000 0000-00-00
0000000000 000.00

000 0000

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea co
0000 000000000
Boston, MA
0 As of 0000
000.00
0000000000 0 000.00

00000000

ud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in re
0000 000000000
Pittsburgh, PA
00 As of 0000
000.00
0000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

T3D Therapeutics Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
EIP Pharma Venture Capital-Backed Boston, MA 0 000.00 0000000000 0 000.00
000000000 00000000 Venture Capital-Backed Pittsburgh, PA 00 000.00 0000000000 000.00
0000 Venture Capital-Backed San Diego, CA 00 00.000 0000000000 0
0000000 Venture Capital-Backed Framingham, MA 00 0000 0000000000 0000
000000 Formerly VC-backed Mountain View, CA 00 00000 000000&0 00000
You’re viewing 5 of 25 competitors. Get the full list »

T3D Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
John Didsbury Ph.D Founder, Chairman of the Board, President & Chief Executive Officer
Stanley Chamberlain Ph.D Chief Scientific Officer
Warren Strittmatter MD Chief Medical Officer
To view T3D Therapeutics’s complete executive team members history, request access »

T3D Therapeutics Board Members (5)

Name Representing Role Since
Barry Buzogany JD T3D Therapeutics Board Member 000 0000
Charles Lineberry Ph.D T3D Therapeutics Board Member 000 0000
John Didsbury Ph.D T3D Therapeutics Founder, Chairman of the Board, President & Chief Executive Officer 000 0000
John Golden Self Board Member 000 0000
Thomas Mendell Self Board Member 000 0000
To view T3D Therapeutics’s complete board members history, request access »

T3D Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

T3D Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institute On Aging Government Minority 000 0000 000000 0
To view T3D Therapeutics’s complete investors history, request access »